Viveve Product Review Financial Analysis and Guidance

NEW YORK, NY / ACCESSWIRE / April 20, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and micro-cap public companies, is issuing a comprehensive report with no obligation on Viveve Medical, Inc (VIVE[1]). Viveve designs, develops, manufactures, and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation.

Viveve demonstrated robust clinical evidence with successful completion of the largest clinical trial for vaginal laxity and sexual function ever conducted. An Investigational Device Exemption (IDE) was submitted in September of 2016 to the Food and Drug Administration (FDA) for authorization to begin the VIveve Treatment of the Vaginal Introitus to EVauate Efficacy (VIVEVE II) study. The study will begin in the U.S. when the FDA completes its review and if approval is received.

An IDE approval could be a bonanza for Viveve. Read about it in this report: READ MORE[2].

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *